Dr. Reddy's Laboratories Ltd.

Industry

  • Pharmaceuticals
    • OTC, Consumer
    • Generic Drugs

Other Names/Subsidiaries

  • Aurigene Discovery Technologies
  • OctoPlus N.V.
  • Promius Pharma LLC
  • Dr. Reddy's Research and Development B.V.
  • Imperial Credit Private Limited
  • Wockhardt Limited
See more in Biomedtracker

Latest on Dr. Reddy's Laboratories Ltd.

Scrip

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From

Generics Bulletin

Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera

 
• By Dave Wallace

Dr Reddy’s has gained rights to a pair of proposed Stelara (ustekinumab) and Simponi (golimumab) biosimilars in multiple markets in south-east Asia, after striking an exclusive commercialization agree

Scrip

Mounjaro In India: Price Differential, Window Of Opportunity

 
• By Anju Ghangurde

Eli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec

Generics Bulletin

Alvotech And Reddy’s Await US Denosumab Decision As Launch Date Closes In

 
• By Dean Rudge

Alvotech’s AVT03 proposed biosimilar to Prolia/Xgeva (denosumab) has been successfully filed by its partner Dr Reddy’s Laboratories with the US Food and Drug Administration, in the latest development